



Perma-Fix Medical Provides Business Update

Schedules Investor Webcast for March 26th at 2:00 PM Central European Time

Warsaw and Atlanta – March 26, 2015 – Perma-Fix Medical S.A. (WAR: PFM), a subsidiary of Perma-Fix Environmental Services, Inc., a NASDAQ listed company, today provided a general business update. The Company also announced it will host a business update call at 2:00 PM Central European time (9:00 a.m. Eastern time) on Thursday, March 26, 2015, via webcast on the company's website: www.medical-isotope.com.

Dr. Louis F. Centofanti, CEO of Perma-Fix Medical, commented, "We are pleased to report that in January we experienced three significant milestones, which have helped advance the rollout of our Technetium-99m (Tc-99m) production process in Europe and the United States. Firstly, the U.S. Patent & Trademark Office issued Perma-Fix Environmental a composition of matter patent for our microporous composite material and its applications. As Perma-Fix Medical has signed an exclusive patent license agreement with Perma-Fix Environmental Services, this patent provides us very broad intellectual property protection. Second, we entered into a letter of intent to form a strategic partnership and secure a \$1 million investment from Digirad Corporation. Digirad, one of the largest national providers of in-office nuclear cardiology imaging services, is an ideal partner that will bring us both medical imaging business and technological expertise, as well as assist us in completion of the final design of a prototype Tech-99m generator. As one of the leading users of Tc-99m in the United States, Digirad will be one of the main buyers of Tc-99m supplied by Perma-Fix Medical. Our third significant move forward was official notification from the National Centre for Research and Development in Poland for a grant award to advance the development of a novel prototype generator for the production of Tc-99m for cancer and cardiac imaging. The total Generator Project budget is approximately 13.3 million PLN (USD \$3.7M), of which Generator Project grant subsidies allocated to the project team will be 10 million PLN (USD \$2.8M). Perma-Fix Medical will directly receive 2.9 million PLN (USD \$0.8M) and the remaining amount will be allocated to other members of the project consortium to support technology development and testing."

Dr. Centofanti continued, "Given the commercial, environmental and political benefits of our process, we believe this technology has the potential to solve the global supply chain issues related to Tc-99m as it meets the global production needs without the use of uranium. We remain extremely encouraged by the outlook for the business, as our process has been validated at leading institutions, including POLATOM in Warsaw, Poland and the Missouri University Research Reactor (MURR) in Columbia. The growing interest in our medical isotope technology within the industry has been further validated by the planned investment and our strategic partnership with Digirad. Looking ahead, we are focused on establishing additional strategic partners involved in the Tc-99m supply chain. Upon completion of our commercial size prototype TC-99m generator later this year, we plan to move ahead with submissions to the FDA and CE. We fully expect to meet both Polish and European Pharmacopeia standards, a prerequisite to the regulatory application process.

Dr. Centofanti added, "As Perma-Fix Medical is still in the development stage, we have carefully managed our expenses and had over 4.2 million PLN of cash with no debt and 14.6 million PLN of shareholders' equity at the end of the fourth quarter, which reflected the recent Polish National Court registration of our private placement equity raise of 2.75 million PLN – 8.25 mil PLN in Poland. We believe the grant funding and the planned \$1 million USD investment from Digirad Corporation, provides us with the required capital to advance development of our medical isotope technology.

Dr. Centofanti concluded, "Awareness of the potential crisis that lies ahead regarding the shortage of medical imaging isotopes around the globe is building and we are pleased to be part of the solution. As we continue to align ourselves with like-minded strategic partners and investors, we are confident that we will realize our vision for a safer and more cost-effective approach to the creation of isotopes used in medical imaging."

The conference call can be accessed via a live Internet webcast on the Company's website at www.medical-isotope.com. A webcast replay of the conference call will be accessible on the Company's website at www.medical-isotope.com for 90 days.

About Perma-Fix Medical

Perma-Fix Medical is a subsidiary of Perma-Fix Environmental Services Inc., a NASDAQ listed company. It was formed to develop, obtain FDA and other regulatory approval and commercialize a new process to produce Technetium-99 (Tc-99m), the most widely used medical isotope in the world. The new process is expected to solve worldwide shortages of Tc-99m as it is less expensive, does not require the use of government-subsidized, weapons-grade materials and can be easily deployed around the world using standard research and commercial reactors, thereby eliminating the need for special purpose reactors.

Please visit us on the World Wide Web at <http://www.medical-isotope.com>.

Contacts:

Justyna Gudaszwaska or David K. Waldman
Crescendo Communications Europe Sp. z.o.o
Tel: (+48 71) 79 11 551
Email : pfm@crescendo-ir.com